Pfizer’s biosimilar to blockbuster anemia meds—Amgen's Epogen and J&J's Procrit—won FDA panel backing Thursday, moving another step closer to a…

Two former Heritage Pharma execs will cooperate with a broad generic pricing probe that's roped in some of the biggest companies in the business.

The FDA issued its first untitled letter of the year for promotional infractions to scold Orexigen Therapeutics for infractions in a Contrave TV ad.

Should drugs that win conditional FDA approval command the same high prices as products that undergo the full menu of agency scrutiny?

Johnson & Johnson is putting behind it the lingering legal problems that stemmed from manufacturing issues that led to recalls some years back.

In the immuno-oncology rivalry between Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo, Keytruda has been running the table. But Opdivo boasts the latest…

A set of women claiming Pfizer’s blockbuster statin Lipitor caused their diabetes have the right to go back to California state court to make their case.

A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…

Roche’s new drug Ocrevus has landed in the same sentence with the three letters all makers of multiple sclerosis drugs dread: PML.